Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with
stage I, stage II, or stage III breast cancer who have tumor cells in the bone marrow.